Trials in Ventura, California
Here are the top 10 medical studies for glioblastoma in Ventura, California
Popular Filters
Phase 3 Trials
Alkylating agents
Lomustine + Standard Therapy for Glioblastoma
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is comparing the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in treating newly diagnosed MGMT methylated glioblastoma.
Procedure
Advanced MRI Imaging for Glioblastoma
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is comparing a new type of MRI imaging called pH weighted chemical exchange saturation transfer (CEST) MRI to the standard MRI imaging for guiding surgical resections in patients with glioblastoma.
Radiation
Personalized Immunotherapy for Glioblastoma
Recruiting1 awardPhase 2 & 3
Los Angeles, California
This trial will study an immunotherapy combining a cancer-patient's own cells and standard treatment to fight glioblastoma. Immune cells will be harvested from the patient, stimulated and expanded, then infused back.
Chemotherapy
Optune + Temozolomide + Pembrolizumab for Brain Cancer
Recruiting1 awardPhase 3
Los Angeles, California
This trial is testing a treatment for newly diagnosed brain cancer patients. They are comparing the effectiveness of a new treatment called Optune with chemotherapy and immunotherapy to a combination of Optune with chemotherapy alone.
Alkylating agents
Multiple Therapies for Glioblastoma
Recruiting1 awardPhase 2 & 3
Los Angeles, California
This trial is testing various treatments for patients with newly diagnosed or returning brain cancer. It adjusts treatments based on how well patients are doing to find the most effective options. The goal is to improve survival rates by matching the best treatments to specific patient types.
Trials With No Placebo
Selective Inhibitor of Nuclear Export
Selinexor + Temozolomide for Recurrent Glioblastoma
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial tests selinexor with temozolomide for patients whose brain cancer has returned. Selinexor blocks a protein that helps cancer cells grow, and temozolomide damages their DNA to kill them or stop their growth. Temozolomide is a DNA methylating drug currently used as a first-line treatment in glioblastoma therapy.
Brachytherapy
GammaTile + Stupp Protocol for Glioblastoma
Recruiting3 awardsPhase 4
Los Angeles, California
This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.